Sangamo Biosciences Inc. (SGMO)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.94-0.06 (-1.20%)
As of 11:46 AM EDT. Market open.
People also watch:
SGENALNYPGNXZIOPHALO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open4.96
Prev Close5.00
Bid4.92 x 2100
Ask4.93 x 200
Day's Range4.90 - 5.02
52wk Range4.08 - 9.91
1y Target EstN/A
Market Cap348.85M
P/E Ratio (ttm)-5.23
Beta2.93
Volume193,471
Avg Vol (3m)912,188
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Sangamo BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : SGMO-US : September 26, 2016
    Capital Cube4 hours ago

    Sangamo BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : SGMO-US : September 26, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Sangamo BioSciences, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Capital Cube5 days ago

    ETF’s with exposure to Sangamo BioSciences, Inc. : September 21, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Sangamo BioSciences, Inc. Here are 5 ETF’s with the largest exposure to SGMO-US. Comparing the performance and risk of Sangamo BioSciences, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PR Newswire20 days ago

    Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX, The First Application Of Therapeutic In Vivo Genome Editing

    RICHMOND, Calif., Sept. 6, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (SGMO), the leader in therapeutic genome editing, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SB-FIX, the company's zinc finger nuclease (ZFN)-mediated genome editing product candidate for the treatment of hemophilia B. Sangamo expects to initiate a Phase 1/2 clinical study (SB-FIX-1501) in adult subjects with the disease in 2016.